ABSTRACT 1 2 Consuming whey protein prior to a meal may reduce postprandial glucose excursions, however 3 optimising timing of supplementation is important to improve its clinical utility. Thirteen centrally-4 obese, insulin resistant males (waist circumference: 121 (SEM 3) cm; HOMA-IR: 6.4 (SEM 1.2)) 5 completed four experimental conditions in a single-blind, crossover design. Participants consumed 6 mixed-macronutrient breakfast and lunch meals on all occasions, with 20 g whey protein consumed 7 15 min prior to (PRE), alongside (DUR) or 15 min post-breakfast (POST), or omitted (CON). 8
Central obesity is associated with insulin resistance and an increased risk of developing type 2 37 diabetes and cardiovascular disease 1,2 . In those without diagnosed type 2 diabetes, postprandial 38 glucose excursions are a stronger predictor of HbA1c than fasting glucose, and also increase the risk 39 of cardiovascular disease [3] [4] [5] . Postprandial hyperglycaemia, no matter how brief, drives inflammation, 40 oxidative stress and vascular dysfunction [6] [7] [8] [9] . Thus, individuals who are centrally-obese and insulin 41 resistant may benefit from strategies that ameliorate postprandial hyperglycaemic excursions 10 . 42 43 Recent non-pharmaceutical interventional studies have sought to reduce postprandial hyperglycaemia 44 through whey protein supplementation (for review 11 ). Whey protein contains an abundant source of 45 amino acids and bioactive peptides that are rapidly digested. These act as potent insulin secretagogues 46 and can reduce gastric emptying, hepatic glucose production, and can increase satiety [12] [13] [14] [15] [16] . Despite 47 many trials in normal-weight populations or individuals with type 2 diabetes, few studies have been 48 conducted using centrally-obese participants without metabolic disease. This is surprising given that 49 such individuals are likely to be exposed to elevated postprandial glycaemic excursions 17 and their 50 associated adverse metabolic effects 18 . 51
52
There are practical limitations associated with implementing pre-meal whey protein as a strategy to 53 reduce postprandial hyperglycaemia. Firstly, studies have investigated the glycaemic response to 54 single test meals of primarily high glycaemic index carbohydrate content 19, 20 , without investigating 55 if the whey supplementation effects carry forward to subsequent meals. Secondly, dosages of whey 56 protein administered are generally unrealistically large (45-55 g; ~200 kcal) 19, 21 . Furthermore, whey 57 protein has shown most benefit when supplemented as a preload around 30 min before the main meal 58 19, 22 , thus restricting its ecological validity when applied in free-living conditions, as this does not 59 reflect conventional eating habits 23 . From a clinical viewpoint it is important to establish whether the 60 beneficial effect of whey supplementation is retained at smaller doses, if the whey bolus is beneficial 61 when consumed alongside or after the meal, and if the therapeutic effects influence glycaemia at 62 subsequent meal times in centrally-obese insulin resistant individuals. 63
64
The purpose of this study was to investigate the effect of a realistic whey protein dose on postprandial 65 metabolic and appetite responses in centrally-obese insulin resistant individuals, using timings and 66 test meals that reflect habitual eating behaviours. We hypothesise that whey protein consumption will 67 reduce the postprandial glucose response and positively affect subjective appetite, with more 68 favourable effects resulting from earlier supplementation. Centrally-obese male participants, free from metabolic disease, were recruited from the local 76 community. Participants who met the inclusion criteria for gender (male), age (18-55 years), waist 77 circumference (>102 cm) and physical activity level (low) were included in the study (n = 13; see 78 The experimental protocol is presented in Figure 1 . Participants arrived at the laboratory at the same 114 time (~08.00 hours) on each occasion following an overnight fast. After insertion of a cannula in an 115 antecubital vein, baseline venous and capillary blood samples were collected and subjective appetite 116 was assessed using visual analogue scales. In the PRE condition, participants consumed a 20 g whey 117 protein beverage, with flavoured water (placebo) provided in all other conditions. After a further 15 118 min, breakfast was consumed in all conditions, accompanied by either a whey protein (DUR) or 119 placebo test drink (POST and CON). At 15 min post-breakfast consumption, a further test drink was 120 provided, with whey protein administered in the POST condition and flavoured water during all other 121 conditions. The remainder of the protocol was identical under all experimental conditions, with blood 122 samples and appetite ratings collected at regular intervals (Figure 1 ). Participants rested in a seated 123 position for 180 min following breakfast consumption, after which a standardised lunch meal was 124 consumed. Following a further period of seated rest (180 min), the cannula was removed and 125 participants were able to leave the laboratory. 126
127

Test meals 128 129
At each test drink time point (15 min before, during or 15 min after breakfast) either a whey protein 130 or placebo drink was consumed which was condition-dependent. The protein drink contained 23g 131 whey protein isolate powder (Lacprodan SP-9225 Instant; Arla Food Ingredients Group, Viby, 132 Denmark) mixed with 150 ml water and 0.5 ml energy-free strawberry flavouring (FlavDrops, 133 Myprotein, UK), providing 20 g protein (87% protein content) and 343 kJ (82 kcal) energy. The 134 placebo drink was matched for volume and taste using similarly flavoured water. All drinks were 135 provided in opaque bottles and no reference was made to which condition was being conducted. When whey was supplemented after the meal, insulinaemia was ~23% greater than CON (P = 0.049). 236
Insulin sensitivity did not significantly differ between conditions during the post-breakfast period 237 There was no effect of condition (P = 0.611) and NEFA AUC was similar between conditions across 244 this period (P = 0.517; Figure 2f of time was present (P < 0.001), such that there was an immediate reduction in combined appetite 269 score following lunch, before gradually returning to pre-lunch levels at 150-180 min post-270 consumption across all conditions (Figure 3c ). There were no significant differences observed in post-271 lunch AUC for combined appetite score (Figure 3d) or its constituent components of hunger, fullness, 272 PFC and satisfaction between conditions (P > 0.05; Table 2 conditions. Post hoc analysis of the main effect of time (P < 0.001) indicated that levels were elevated 278 above baseline concentration from 60 min post-breakfast onwards (P ≤ 0.018), and continued to rise 279 throughout (Figure 5a ). There was no effect of condition on triglyceride concentrations (P = 0.653), 280
and AUC was similar between conditions for triglyceride response across the full postprandial period 281 (P = 0.64; Figure 5b 17.0% and 9.2% when whey was consumed before or alongside the meal respectively. Additionally, 305 a 7.3% decrease in glucose AUC across the postprandial period was observed following the whey 306 preload, devoid of any significant change in insulin AUC. Whilst it is understood that postprandial 307 hyperglycaemia is predictive of various complications and metabolic derangements, as described 308 above, the clinical significance of such a reduction in glucose AUC of the magnitude shown in our 309 study, in terms of translation to a clinical end point, remains unclear. 310
311
The mechanisms explaining the reduction in postprandial glycaemia are yet to be fully elucidated. 312
Our data contrast with prior literature 19, 21 , in that the insulin concentrations were not elevated during 313 the postprandial period with the preload supplementation strategy. However, at the onset of the 314 breakfast ingestion, we observed raised insulin concentrations under PRE in comparison to CON 315 (Figure 2) . A reduction in the early postprandial insulin response to feeding is a characteristic 316 associated with insulin resistance and type 2 diabetes 37 , and thus the raised insulin may have 317 contributed to clearing glucose, suppressing hepatic glucose output, and opposing the potential rise 318 in glucagon that can occur with protein feeding. Furthermore, consuming whey as a preload is known 319 to slow gastric emptying 19 . Thus, a combined influence of raised insulin concentrations prior to meal 320 ingestion and a slower rate of gastric emptying could explain the superior influence of the preload 321 strategy on reducing postprandial glycaemia. This explanation is supported by insulin concentrations 322 that were similar between DUR and CON, yet glycaemia was significantly lower with DUR. 323
Moreover, insulin concentrations were elevated with post-meal supplementation, without any 324 improvement in glycaemia. 325
326
The effects of whey protein ingestion, independent of timing of consumption, were limited to glucose 327 and insulin responses in the current study. Postprandial lipaemia was not affected by co-ingestion of 328 whey protein with breakfast, which is in line with previous findings in normal-weight males 28 and 329 those with and without type 2 diabetes 38 , but differs from the findings of Pal et al.
. Pal and 330
colleagues observed a 21% reduction in plasma triglyceride AUC following 45 g whey, compared 331 with the same dose of glucose, when administered alongside a mixed-macronutrient meal in obese 332 females. Such a disparity cannot be attributed to differences in fat content of test meals, as 333 postprandial triglyceride was unaffected when relatively low (the present study) and high 38 fat test 334 meals have been supplemented with prior whey protein. The amount of supplemental whey 335 administered by Pal et al. however, was over 2-fold greater than both these studies, which may have 336 influenced the observed triglyceride-lowering effect. 337 338 Subjective appetite appeared to be unaffected by whey protein supplementation, regardless of 339 condition. Prior research has demonstrated an appetite suppressing effect of whey protein, with wide 340 ranging protocols and participants, e.g. in overweight males after a 55 g preload 40 and with a 15 g 341 whey bolus in type 2 diabetes 16 . In the study by King et al. pre-meal whey protein resulted in greater 342 post-meal insulin concentrations compared to control, possibly playing a role in appetite 343 suppressession 41, 42 . However, in the current study the elevated pre-meal insulin during PRE, and the 344 greater insulin during POST, did not translate into changes in appetite sensations. A mixed effect of 345 whey on subjective appetite ratings in non-diabetic individuals has previously been shown. Several 346 studies have reported reductions in appetite [43] [44] [45] , although the exact mechanisms remain to be 347 elucidated, while others show no effect on perceptions of appetite with 46, 47 
